Infection and Drug Resistance (Oct 2022)

Multicenter Italian Study on “In Vitro Activities” of Isavuconazole, Voriconazole, Amphotericin B, and Caspofungin for Aspergillus Species: Comparison between SensititreTM YeastOneTM and MIC Test Strip

  • Lo Cascio G,
  • Bazaj A,
  • Trovato L,
  • Sanna S,
  • Andreoni S,
  • Blasi E,
  • Conte M,
  • Fazii P,
  • Oliva E,
  • Lepera V,
  • Lombardi G,
  • Farina C

Journal volume & issue
Vol. Volume 15
pp. 5839 – 5848

Abstract

Read online

Giuliana Lo Cascio,1– 3 Alda Bazaj,1 Laura Trovato,2,4 Silvana Sanna,2,5 Stefano Andreoni,2,6 Elisabetta Blasi,2,7 Marco Conte,2,8 Paolo Fazii,2,9 Ester Oliva,10 Valentina Lepera,11 Gianluigi Lombardi,2,11 Claudio Farina2,10 1Clinical Microbiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; 2Medical Mycology Committee, Italian Society of Clinical Microbiologist, Milan, Italy; 3Clinical Microbiology and Virology Unit, Azienda USL, Piacenza, Italy; 4Clinical Microbiology, Azienda Ospedaliera Universitaria- Policlinico Vittorio Emanuele, Catania, Italy; 5Microbiology and Virology Unit, Azienda Ospedaliera Universitaria, Sassari, Italy; 6Microbiology and Virology Unit, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy; 7Clinical Microbiology, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy; 8Microbiology and Virology Unit, Grande Ospedale Metropolitano Bianchi- Melacrino- Morelli, Reggio, Calabria, Italy; 9Clinical Microbiology and Virology P.O. Spirito Santo, Pescara, Italy; 10Clinical Microbiology and Virology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 11Clinical Microbiology, ASST Grande Ospedale Metropolitano Niguarda, Milan, ItalyCorrespondence: Giuliana Lo Cascio, Email [email protected]: In this study the activity of Isavuconazole, Voriconazole, Amphotericin B, and Caspofungin against 224 clinical isolates of Aspergillus spp. originating from seven Italian hospitals, was comparatively evaluated with two commercial antifungal susceptibility tests (AST): SensititreTM YeastOneTM (SYO) and MIC Test Strip. More attention was focused on Isavuconazole activity, given the new introduction of the drug in widely distributed antifungal susceptibilities methods in the clinical microbiology lab. The minimum inhibitory concentrations of antifungal drug that can inhibit the growth of pathogen by 90% (MIC90) for Isavuconazole detected by SYO were 0.5, 1, 0.25, and 2 μg/mL for Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Aspergillus niger, respectively, whilst they were 0.25, 0.25, 0.5, and 0.75 μg/mL by MIC Test Strip. Essential agreement between the two tested methods for Isavuconazole is 70% for all the species tested, 75.7% for A. fumigatus, 45.2% for A. flavus, 90.6% for A. terreus, and 40% for A. niger. Although the tested strains do not express any phenotypic resistance, MIC results were quite different if tested with microdilution broth or gradient agar method. This is the first Italian multicenter report on Isavuconazole MIC obtained employing the widely used SensititreTM Yeast OneTM (SYO) and MIC Test Strip on clinical isolates of Aspergillus.Keywords: antifungal susceptibilities, Aspergillus Isavuconazole susceptibilities, Sensititre and MIC Test Strip

Keywords